Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial

What Was Tested

Researchers studied Somatostatin and Lanreotide in this observational study publication.

Clinical trials.gov NCT01354405 (REGISTRATION: 13 May 2011).

Who Took Part

According to the abstract, 4 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a open-label study.

Nothing was hidden in this open-label Somatostatin study: the patients and staff both knew the treatment.

The methods mention a period of 6 months.

Primary outcome was change in liver volume after 6 months; secondary outcomes were changes in kidney volume, estimated glomerular filtration rate (eGFR), symptom relief and health-related quality of life (Euro-Qol5D).

The researchers used the Wilcoxon signed-rank test or paired two-sided t-test to analyze within-group differences.

What Was Measured

Topics PubMed links to this paper include Cysts, Glomerular Filtration Rate, Kidney, Liver, Liver Diseases, Organ Size and Peptides, Cyclic.

The authors tagged it with the keywords ADPKD, polycystic liver disease, quality of life and somatostatin analogues.

What This Means in Plain Language

The paper is an open-label study of Somatostatin and Lanreotide in 4 patients over 6 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2015 (Liver international : official journal of the International Association for the Study of the Liver), a journal based in United States.

More context: the Somatostatin compound page and the Lanreotide compound page, all human trials.